Compare Northrop Grumman Corporation (NOC) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Northrop Grumman Corporation vs Pfizer Inc — how do they compare? Northrop Grumman Corporation trades at $516.8 (market cap $73.16B), while Pfizer Inc trades at $27.91 (market cap $158.39B). The key difference: Pfizer Inc is far larger — about 2.2× Northrop Grumman Corporation's market cap, and Pfizer Inc pays the higher dividend (6.19%). Which is the better fit depends on your goals.
| NOC | PFE | |
|---|---|---|
Market Cap | $73.16B | $158.39B |
Sector | Industrials | Health |
52-Week High | $768.02 | $29.02 |
52-Week Low | $496.02 | $23.60 |
Enterprise Value | $87.14B | $209.89B |
Dividend Yield | 1.92% | 6.19% |
Volume | — | 29,869,932 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Northrop Grumman (NOC) trades at $518.58, up 0.7% with strong earnings beats in recent quarters. Technical indicators show a bearish trend with oversold RSI signals, while fundamentals remain solid with 10.48% net margin and 26.96% ROE. The company maintains a record $105 billion backlog and raised guidance after strong Q2 results, supported by rising defense spending globally.
NOC presents a compelling value with a 16.37 P/E below industry averages and a $618.43 consensus price target implying 19% upside. Risks include execution on massive contracts and defense budget volatility, but analyst sentiment is strongly bullish with 57% buy ratings. The stock offers defensive growth exposure amid geopolitical tensions.
Pfizer (PFE) trades at $27.78, down 2.36% today, with a consensus price target of $28.33 suggesting modest upside. The stock shows mixed technical signals with bullish moving averages but neutral oscillators. Recent earnings have consistently beaten expectations, though revenue declined from pandemic peaks. The company maintains strong cash flow generation and a solid dividend yield of approximately 3.1%.
Pfizer presents a value opportunity with reasonable valuation metrics and dividend stability, but faces headwinds from post-COVID revenue normalization and patent expirations. The company's pipeline progress in obesity and oncology could drive future growth, though execution risks remain. Analyst sentiment leans cautious with 59% hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
